Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Upfront Chemotherapy for High Volume HSPC, Single Institute Experience of Southern Taiwan

Date

24 Nov 2018

Session

Poster display - Cocktail

Presenters

Chia-Mu Tsai

Citation

Annals of Oncology (2018) 29 (suppl_9): ix67-ix73. 10.1093/annonc/mdy434

Authors

C. Tsai1, J. Lin1, C. Yu2, T. Wu2, I. Cheng2, M. He2

Author affiliations

  • 1 Urology, Kaohsiung Veterans General Hospital, 813 - Kaohsiung/TW
  • 2 Urology, Kaohsiung Veterans General Hospital, 81362 - Kaohsiung/TW
More

Resources

Background

Androgen-deprivation therapy (ADT) has been the standard of care for advanced prostate cancer since the 1940s. According to the CHAARTED trial, upfront chemotherapy improved overall survival and time to progression in high volume metastatic hormone-sensitivity prostate cancer (mHSPC). We present our experience about upfront chemotherapy for high volume mHSPC.

Methods

14 men with high volume metastatic, hormone-sensitive prostate cancer received upfront docetaxel chemotherapy within the first 3 months of ADT. 56 patients with high volume metastatic hormone-sensitive prostate cancer received ADT alone. Primary end-point is the time to biochemical failure and 2nd end-point is the rate of nadir PSA level less than 1 ng per milliliter.

Results

A total of 14 patients received combination of ADT and Docetaxel chemotherapy. (Median age 71.5, range from 48 to 83 years old; medina iPSA 424.4 ng/ml, range from 15.71 to 2293; one patient has Gleason 7, one has Gleason 8, eight have Gleason 9 and three patinets have Gleason 10; three patients have visceral metastasis). Eight patients had biochemical progression (the median time 9.5 months; and range: from 2 months to 18 months). Fifty percent (7/14) of the patient had their nadir PSA level less than 1 ng per milliliter after upfront chemotherapy. 56 patients were received ADT alone. (Median age 73.5, range from 52- to 85-year-old; Medina iPSA 311.5 ng/ml, range from 9.69 to 8403; three patients have Gleason 7, seven patients have Gleason 8, 33patients have Gleason 9 and seven patients have Gleason 10; five patients have visceral metastasis. 33% (17/51) of patients had nadir PSA level less than 1 ng per milliliter after ADT alone. Although the median time of biochemical failure of ADT with chemotherapy versus ADT alone was 9.5 months versus 12 months, the other six patients received ADT with chemotherapy still do not achieve biochemical failure (39 Ms, 24 Ms, 24 Ms, 12 Ms, 9 Ms, 8 Ms).

Conclusions

In our early experience of upfront chemotherapy, combining with ADT was well tolerable. The combination seemed to augment the tumor control in high risk mHSPC.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Jen-Tai Lin.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings